GoodRx and Novo Nordisk Collaborate to Expand Access to Ozempic and Wegovy for $499/Month

GoodRx has partnered with Novo Nordisk to offer Ozempic and Wegovy pens for $499/month for eligible self-paying patients starting August 18, 2025. This collaboration aims to expand access to these in-demand GLP-1 medications for those without adequate insurance coverage, meeting the growing demand of nearly 17 million people who came to GoodRx for savings and information on GLP-1 medications last year.

GoodRx, a leading platform for medication savings in the U.S., has partnered with Novo Nordisk to offer Ozempic and Wegovy pens for $499 per month for eligible self-paying patients. This collaboration, announced on August 18, 2025, aims to expand access to these in-demand GLP-1 medications for those without adequate insurance coverage. The new pricing represents a significant milestone in improving access and affordability of these critical, FDA-approved treatments.

The collaboration will make Ozempic and Wegovy pens available at over 70,000 retail pharmacies nationwide, starting today. This initiative is particularly timely, given the growing demand for GLP-1 medications. According to GoodRx, nearly 17 million people visited the platform last year seeking savings and information on GLP-1 medications, a 22% increase from the previous year [1].

Wendy Barnes, President and Chief Executive Officer of GoodRx, highlighted the importance of this partnership, stating, "Demand for GLP-1 medications is at an all-time high, but too many Americans still face barriers accessing them. By partnering with Novo Nordisk, we're taking a significant step forward in making these innovative brand-name treatments more accessible for millions of people who need them" [1].

Dave Moore, Executive Vice President, US Operations of Novo Nordisk Inc., emphasized the mission of improving access to effective FDA-approved treatments. "Improving access to effective FDA-approved treatment is central to our mission, and our collaboration with GoodRx allows us to reach those who seek savings and support from their trusted and established platform," he said [1].

This partnership comes as Novo Nordisk is involved in legal battles over compounded versions of GLP-1 medications. The pharmaceutical giant has sued over 130 entities for selling compounded versions of Ozempic and Wegovy, arguing that these drugs are a violation of intellectual property laws and potentially dangerous to patients due to their lack of FDA approval [2].

GoodRx's stock has responded positively to the news, with shares soaring over 30% since the market close [2]. This collaboration is expected to further solidify GoodRx's position as a key player in the healthcare ecosystem, connecting consumers, healthcare professionals, payers, PBMs, pharma manufacturers, and retail pharmacies to make saving on medications easier.

References:
[1] https://investors.goodrx.com/news-releases/news-release-details/goodrx-announces-collaboration-novo-nordisk-expand-access
[2] https://www.fastcompany.com/91387500/gdrx-goodrx-stock-soars-today-strikes-deal-to-sell-ozempic-wegovy-after-novo-nordisk-breakup-with-hims-hers-health